Hypoxia inducible factor-1 as a target for neurodegenerative diseases

Z. Zhang, Jingqi Yan, Y. Chang, S. ShiDu Yan, H. Shi

Research output: Contribution to journalReview article

59 Citations (Scopus)

Abstract

Hypoxia inducible factor-1 (HIF-1) is a transcriptional factor responsible for cellular and tissue adaption to low oxygen tension. HIF-1, a heterodimer consisting of a constitutively expressed β subunit and an oxygen-regulated β subunit, regulates a series of genes that participate in angiogenesis, iron metabolism, glucose metabolism, and cell proliferation/survival. The activity of HIF-1 is controlled by post-translational modifications on different amino acid residues of its subunits, mainly the alpha subunit. Besides in ischemic stroke (see review [1]), emerging evidence has revealed that HIF-1 activity and expression of its down-stream genes, such as vascular endothelial growth factor and erythropoietin, are altered in a range of neurodegenerative diseases. At the same time, experimental and clinical evidence has demonstrated that regulating HIF-1 might ameliorate the cellular and tissue damage in the neurodegenerative diseases. These new findings suggest HIF-1 as a potential medicinal target for the neurodegenerative diseases. This review focuses on HIF-1α protein modifications and HIF-1's potential neuroprotective roles in Alzheimer's (AD), Parkinson's (PD), Huntington's diseases (HD), and amyotrophic lateral sclerosis (ALS).

Original languageEnglish (US)
Pages (from-to)4335-4343
Number of pages9
JournalCurrent Medicinal Chemistry
Volume18
Issue number28
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Neurodegenerative diseases
Hypoxia-Inducible Factor 1
Neurodegenerative Diseases
Metabolism
Genes
Tissue
Oxygen
Huntington Disease
Amyotrophic Lateral Sclerosis
Cell proliferation
Post Translational Protein Processing
Erythropoietin
Vascular Endothelial Growth Factor A
Cell Survival
Iron
Stroke
Cell Proliferation
Amino Acids
Glucose

Keywords

  • 2-oxoglutarate analogues
  • AD
  • ALS
  • Cobalt
  • EPO
  • HD
  • HIF-1
  • Iron chelator
  • PD
  • Prolyl hydroxylase inhbitor
  • Protein modification
  • VEGF

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Hypoxia inducible factor-1 as a target for neurodegenerative diseases. / Zhang, Z.; Yan, Jingqi; Chang, Y.; ShiDu Yan, S.; Shi, H.

In: Current Medicinal Chemistry, Vol. 18, No. 28, 01.10.2011, p. 4335-4343.

Research output: Contribution to journalReview article

Zhang, Z. ; Yan, Jingqi ; Chang, Y. ; ShiDu Yan, S. ; Shi, H. / Hypoxia inducible factor-1 as a target for neurodegenerative diseases. In: Current Medicinal Chemistry. 2011 ; Vol. 18, No. 28. pp. 4335-4343.
@article{eb208ebd121d4aed945efdb669980bac,
title = "Hypoxia inducible factor-1 as a target for neurodegenerative diseases",
abstract = "Hypoxia inducible factor-1 (HIF-1) is a transcriptional factor responsible for cellular and tissue adaption to low oxygen tension. HIF-1, a heterodimer consisting of a constitutively expressed β subunit and an oxygen-regulated β subunit, regulates a series of genes that participate in angiogenesis, iron metabolism, glucose metabolism, and cell proliferation/survival. The activity of HIF-1 is controlled by post-translational modifications on different amino acid residues of its subunits, mainly the alpha subunit. Besides in ischemic stroke (see review [1]), emerging evidence has revealed that HIF-1 activity and expression of its down-stream genes, such as vascular endothelial growth factor and erythropoietin, are altered in a range of neurodegenerative diseases. At the same time, experimental and clinical evidence has demonstrated that regulating HIF-1 might ameliorate the cellular and tissue damage in the neurodegenerative diseases. These new findings suggest HIF-1 as a potential medicinal target for the neurodegenerative diseases. This review focuses on HIF-1α protein modifications and HIF-1's potential neuroprotective roles in Alzheimer's (AD), Parkinson's (PD), Huntington's diseases (HD), and amyotrophic lateral sclerosis (ALS).",
keywords = "2-oxoglutarate analogues, AD, ALS, Cobalt, EPO, HD, HIF-1, Iron chelator, PD, Prolyl hydroxylase inhbitor, Protein modification, VEGF",
author = "Z. Zhang and Jingqi Yan and Y. Chang and {ShiDu Yan}, S. and H. Shi",
year = "2011",
month = "10",
day = "1",
doi = "10.2174/092986711797200426",
language = "English (US)",
volume = "18",
pages = "4335--4343",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "28",

}

TY - JOUR

T1 - Hypoxia inducible factor-1 as a target for neurodegenerative diseases

AU - Zhang, Z.

AU - Yan, Jingqi

AU - Chang, Y.

AU - ShiDu Yan, S.

AU - Shi, H.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Hypoxia inducible factor-1 (HIF-1) is a transcriptional factor responsible for cellular and tissue adaption to low oxygen tension. HIF-1, a heterodimer consisting of a constitutively expressed β subunit and an oxygen-regulated β subunit, regulates a series of genes that participate in angiogenesis, iron metabolism, glucose metabolism, and cell proliferation/survival. The activity of HIF-1 is controlled by post-translational modifications on different amino acid residues of its subunits, mainly the alpha subunit. Besides in ischemic stroke (see review [1]), emerging evidence has revealed that HIF-1 activity and expression of its down-stream genes, such as vascular endothelial growth factor and erythropoietin, are altered in a range of neurodegenerative diseases. At the same time, experimental and clinical evidence has demonstrated that regulating HIF-1 might ameliorate the cellular and tissue damage in the neurodegenerative diseases. These new findings suggest HIF-1 as a potential medicinal target for the neurodegenerative diseases. This review focuses on HIF-1α protein modifications and HIF-1's potential neuroprotective roles in Alzheimer's (AD), Parkinson's (PD), Huntington's diseases (HD), and amyotrophic lateral sclerosis (ALS).

AB - Hypoxia inducible factor-1 (HIF-1) is a transcriptional factor responsible for cellular and tissue adaption to low oxygen tension. HIF-1, a heterodimer consisting of a constitutively expressed β subunit and an oxygen-regulated β subunit, regulates a series of genes that participate in angiogenesis, iron metabolism, glucose metabolism, and cell proliferation/survival. The activity of HIF-1 is controlled by post-translational modifications on different amino acid residues of its subunits, mainly the alpha subunit. Besides in ischemic stroke (see review [1]), emerging evidence has revealed that HIF-1 activity and expression of its down-stream genes, such as vascular endothelial growth factor and erythropoietin, are altered in a range of neurodegenerative diseases. At the same time, experimental and clinical evidence has demonstrated that regulating HIF-1 might ameliorate the cellular and tissue damage in the neurodegenerative diseases. These new findings suggest HIF-1 as a potential medicinal target for the neurodegenerative diseases. This review focuses on HIF-1α protein modifications and HIF-1's potential neuroprotective roles in Alzheimer's (AD), Parkinson's (PD), Huntington's diseases (HD), and amyotrophic lateral sclerosis (ALS).

KW - 2-oxoglutarate analogues

KW - AD

KW - ALS

KW - Cobalt

KW - EPO

KW - HD

KW - HIF-1

KW - Iron chelator

KW - PD

KW - Prolyl hydroxylase inhbitor

KW - Protein modification

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=80052929099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052929099&partnerID=8YFLogxK

U2 - 10.2174/092986711797200426

DO - 10.2174/092986711797200426

M3 - Review article

C2 - 21861815

AN - SCOPUS:80052929099

VL - 18

SP - 4335

EP - 4343

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 28

ER -